Aminoglycosides: Nephrotoxicity

Antimicrobial Agents and Chemotherapy

Volumn 43, Issue 5, 1999, Pages 1003-1012

  Mingeot Leclercq, Marie Paule ^a   Tulkens, Paul M ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; AMIKACIN; AMINOGLYCOSIDE; ASCORBIC ACID; ASTROMICIN; BICARBONATE; CALCIUM; CALCIUM CHANNEL BLOCKING AGENT; DACTIMICIN; DAPTOMYCIN; DEFEROXAMINE; DEXTRAN SULFATE; DIBEKACIN; FLEROXACIN; FORTIMICIN; FOSFOMYCIN; HABEKACIN; INOSITOL HEXASULFATE; ISEPAMICIN; KANAMYCIN A; KANAMYCIN B; LATAMOXEF; LYSINE; NETILMICIN; PIPERACILLIN; POLYASPARTIC ACID; PYRIDOXAL 5 PHOSPHATE; SAIREI TO; SELENIUM; THIAMAZOLE; THIOCTIC ACID; TOBRAMYCIN; TORBAFYLLINE; ULINASTATIN; UNINDEXED DRUG;

ADAPTATION; CELL STRUCTURE; DRUG BINDING; DRUG EFFECT; DRUG INHIBITION; DRUG MECHANISM; DRUG MEGADOSE; DRUG STRUCTURE; ENZYME ACTIVITY; HUMAN; KIDNEY FAILURE; KIDNEY PARENCHYMA; KIDNEY TUBULE NECROSIS; MOLECULAR MODEL; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; SHORT SURVEY; TISSUE DISTRIBUTION;

EID: 0032952405     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.43.5.1003     Document Type: Short Survey

References (143)

1. Ademuyiwa, O., E. O. Ngaha, and F. O. Ubah. 1990. Vitamin E and selenium in gentamicin nephrotoxicity. Hum. Exp. Toxicol. 9:281-288.
2. Ali, M. Z., and M. B. Goetz. 1997. A meta-analysis of the relative efficacy and toxicity of single daily dosing versus multiple daily dosing of aminoglycosides. Clin. Infect. Dis. 24:796-809.
3. Appelkvist, E. L., M. Soderstrom, L. Nassberger, C. Damberg, G. Dallner, and J. W. DePierre. 1991. Characterization of the lipid and protein contents of myelin bodies isolated from the renal cortex of gentamicin-treated rats. Biochem. Biophys. Res. Commun. 181:894-901.
4. Assael, B. M., C. Chiabrando, L. Gagliardi, A. Noseda, F. Bamonte, and M. Salmona. 1985. Prostaglandins and aminoglycoside nephrotoxicity. Toxicol. Appl. Pharmacol. 78:386-394.
5. Aynedjian, H. S., D. Nguyen, H. Y. Lee, L. B. Sablay, and N. Bank. 1988. Effects of dietary electrolyte supplementation on gentamicin nephrotoxicity. Am. J. Med. Sci. 295:444-452.
6. Bailey, T. C., J. R. Little, B. Littenberg, R. M. Reichley, and W. C. Dunagan. 1997. A meta-analysis of extended-interval dosing versus multiple daily dosing of aminoglycosides. Clin. Infect. Dis. 24:786-795.
7. Barza, M., J. P. Ioannidis, J. C. Cappelleri, and J. Lau. 1996. Single or multiple daily doses of aminoglycosides: a meta-analysis. Br. Med. J. 312: 338-345.
8. Beauchamp, D., C. Guimont, L. Grenier, M. LeBrun, D. Tardif, P. Gourde, M. G. Bergeron, L. Thilbault, and G. Labrecque. 1997. Time-restricted feeding schedules modify temporal variation of gentamicin experimental nephrotoxiciry. Antimicrob. Agents Chemother. 41:1468-1474.
9. Beauchamp, D., G. Laurent, L. Grenier, P. Gourde, J. Zanen, J. A. Heuson-Stiennon, and M. G. Bergeron. 1997. Attenuation of gentamicin induced nephrotoxicity in rats by fleroxacin. Antimicrob. Agents Chemother. 41: 1237-1245.
10. Begg, E. J., and M. L. Barclay. 1995. Aminoglycosidcs - 50 years on. Br. J. Clin. Pharmacol. 39:597-603.
11. Ben-Ismail, T. H., B. H. Ali, and A. A. Bashir. 1994. Influence of iron, deferroxamine and ascorbic acid on gentamicin-induced nephrotoxicity in rats. Gen. Pharmacol. 25:1249-1252.
12. Bertino, J. S., and J. C. Rotschafer. 1997. Editorial response: single daily dosing of aminoglycosides. A concept whose time has not yet come. Clin. Infect. Dis. 24:820-823.
13. Blaser, J., and C. Konig. 1995. Once-daily dosing of aminoglycosides. Eur. J. Clin. Microbiol. Infect. Dis. 14:1029-1038.
14. Blum, D. 1995. An overview of the safety of isepamicin in adults. J. Chemother. 7(Suppl. 2):87-93.
15. Brown, G. C., R. C. Eagle, E. P. Shakin, M. Gruber, and V. V. Arbizio. 1990 Retinal toxicity of intravitreal gentamicin. Arch. Ophthalmol. 108:1740-1744.
16. Carlier, M. B., G. Laurent, P. J. Claes, H. J. Vanderhaeghe, and P. M. Tulkens. 1983. Inhibition of lysosomal phospholipases by aminoglycoside antibiotics: in vitro comparative studies. Antimicrob. Agents Chemother. 23:440-449.
17. Carrier, D., N. Chartrand, and W. Matar. 1997. Comparison of the effects of amikacin and kanamycins A and B on dimyristoylphosphatidylglycerol bilayers. Biochem. Pharmacol. 53:401-408.
18. Casteels-Van Daele, M., L. Corbeel, W. Van de Casseye, and L. Standaert. 1980. Gentamicin-induced Fanconi syndrome. J. Pediatr. 97:507-508. (Letter.)
19. Chiu, P. J. S., G. H. Miller, J. F. Long, and J. A. Waitz. 1979. Renal uptake and nephrotoxicity of gentamicin during urinary alkalinization in rats. Clin. Exp. Pharmacol. Physiol. 6:317-326.
20. Chung, L., G. Kaloyanides, R. McDaniel, A. McLaughin, and S. McLaughin. 1985. Interaction of gentamicin and spermine with bilayer membranes containing negatively-charged phospholipids. Biochemistry 24: 442-452.
21. Cohen, R., K. Johnson, and H. D. Humes. 1988. Potentiation of aminoglycoside nephrotoxicity by vitamin-D-induced hypercalcemia. Miner. Electrolyte Metab. 14:121-128.
22. De Broe, M. E., G. J. Paulus, G. A. Verpooten, F. Roels, N. Buyssens, R. Wedeen, and P. M. Tulkens. 1984. Early effects of gentamicin, tobramycin and amikacin on the human kidney. Kidney Int. 25:643-652.
23. Dominguez, J. H., C. C. Hale, and M. Qulali. 1996. Studies of renal injury. I. Gentamicin toxicity and expression of basolateral transporters. Am. J. Physiol. 27:F245-F253.
24. Elfarra, A. A., R. J. Duescher, P. J. Sausen, T. M. O'Hara, and A. J. Cooley. 1994. Methimazole protection of rats against gentamicin-induced nephrotoxicity. Can. J. Physiol. Pharmacol. 72:1238-1244.
25. Elliott, W. C., and D. S. Patchin. 1992. Aminoglycoside-mediated calciuresis. J. Pharmacol. Exp. Ther. 262:151-156.
26. Elliott, W. C., and D. S. Patchin. 1995. Effects and interactions of gentamicin, polyaspartic acid and diuretics on urine calcium concentration. J. Pharmacol. Exp. Ther. 273:280-284.
27. Elliott, W. C., D. C. Houghlon, D. N. Gilbert, J. Baines-Hunter, and W. M. Bennett. 1982. Gentamicin nephrotoxicity. I. Degree and permanence of acquired insensitivity. J. Lab. Clin. Med. 100:501-512.
28. Elliott, W. C., D. C. Houghton, D. N. Gilbert, J. Baines-Hunter, and W. M. Bennett. 1982. Gentamicin nephrotoxicity. II. Definition of conditions necessary to induce acquired insensitivity. J. Lab. Clin. Med. 100:513-525.
29. Elliott, W. C., R. A. Parker, D. C. Houghton, D. N. Gilbert, G. A. Porter, J. DeFehr, and W. M. Bennett. 1980. Effect of sodium bicarbonate and ammonium chloride ingestion in experimental gentamicin nephrotoxicity in rats. Res. Commun. Chem. Pathol. Pharmacol. 28:483-495.
30. Fabre, J., M. Rudhardt, P. Blanchard, C. Regamey, and P. Chauvin. 1976. Persistence of sisomicin and gentamicin in renal cortex and medulla compared with other organs and serum of rats. Kidney Int. 10:444-449.
31. Fauconneau, B., C. Tallineau, F. Huguet, and A. Piriou. 1995. Gentamicin-induced kidney damage and lipid peroxidation in rats. Toxicol. Lett. 76: 127-134.
32. Ford, D. M., R. E. Thieme, C. A. Lamp, S. J. Covington, and B. A. Molitoris. 1995. HWA-448 reduces gentamicin toxiciry in LLC-PK1 cells. J. Pharmacol. Exp. Ther. 274:29-33.
33. Fujita, K., H. M. Fujita, and Y. Aso. 1983. Protective effect of fosfomycin against renal accumulation of aminoglycoside antibiotics. Jpn. J. Antibiot. 36:3392-3394.
34. +-ATPase in rat kidney cells. Acta Physiol. Scand. 141:27-34.
35. Gilbert, D. N. 1995. Aminoglycosides, p. 279-306. In C. L. Mandell, J. E. Bennett, and R. Dolin (ed.), Principles and practice of infectious diseases, 4th ed. Churchill Livingstone, New York, N.Y.
36. Gilbert, D. N. 1997. Editorial response: meta-analyses are no longer required for determining the efficacy of single daily dosing of aminoglycosides. Clin. Infect. Dis. 24:816-819.
37. Gilbert, D. N., C. A. Woods, S. J. Kohlhepp, P. W. Kohnen, D. C. Houghton, H. C. Finkbeiner, and W. M. Bennett. 1989. Polyaspartic acid prevents experimental aminoglycoside nephrotoxicity. J. Infect. Dis. 159:945-953.
38. Giuliano, R. A., G. J. Paulus, G. A. Verpooten, V. M. Pattijn, D. E. Pollet, E. J. Nouwen, and M. E. De Broe. 1984. Recovery of cortical phospholipidosis and necrosis after acute gentamicin loading in rats. Kidney Int. 24:838-847.
39. Giuliano, R. A., G. A. Verpooten, L. Verbist, R. Wedeen, and M. E. De Broe. 1986. In vivo uptake kinetics of aminoglycosides in the kidney cortex of rats. J. Pharmacol. Exp. Ther. 236:470-475.
40. Giurgea-Marion, L., G. Toubeau, G. Laurent, J. Heuson-Stiennon, and P. M. Tulkens. 1986. Impairment of lysosome-pinocytic vesicle fusion in rat kidney proximal tubules after treatment with gentamicin at low doses. Toxicol. Appl. Pharmacol. 86:271-285.
41. Gurnani, K., H. Khouri, M. Couture, M. G. Bergeron, D. Beauchamp, and D. Carrier. 1995. Molecular basis of the inhibition of gentamicin nephrotoxicity by daptomycin: an infrared spectroscopic investigation. Biochem. Biophys. Acta 1237:86-94.
42. Hammond, T. G., R. R. Majewski, J. H. Kaysen, F. O. Goda, G. L. Navar, F. Pontillon, and P. J. Verroust. 1997. Gentamicin inhibits rat renal cortical homotypic endosomal fusion: role of megalin. Am. J. Physiol. 272:F117-F123.
43. Hatala, R., T. T. Dinh, and D. J. Cook. 1997. Single daily dosing of aminoglycosides in immunocompromised adults: a systematic review. Clin. Infect. Dis. 24:810-815.
44. Hayashi, T., Y. Watanabe, K. Kumano, R. Kitayama, T. Yasuda, I. Saikawa, and K. Shimizu. 1988. Protective effect of piperacillin against nephrotoxicity of cephaloridine and gentamicin in animals. Antimicrob. Agents Chemother. 32:912-918.
45. Hishida, A., T. Nakajima, M. Yamada, A. Kato, and N. Honda. 1994. Roles of hemodynamic and tubular factors in gentamicin-mediated nephropathy. Renal Fail. 16:109-116.
46. Hori, R., M. Okuda, Y. Ohishi, M. Yasuhara, and M. Takano. 1992. Surface binding and intracellular uptake of gentamicin in the cultured kidney epithelial cell line (LLC-PK1). J. Pharmacol. Exp. Ther. 261:1200-1205.
47. + dependent D-glucose transport in rabbit kidney brush-border membrane vesicles. Biochim. Biophys. Acta 858:153-160.
48. Hostetler, K. Y., and L. B. Hall. 1982. Aminoglycoside antibiotics inhibit lysosomal phospholipase A and C from rat liver in vitro. Biochim. Biophys. Acta 710:506-509.
49. Houghton, D. C., D. Lee, D. N. Gilbert, and W. M. Bennett 1986. Chronic gentamicin nephrotoxicity. Continued tubular injury with preserved glomerular filtration function. Am. J. Pathol. 123:183-194.
50. Hulka, G. F., J. Prazma, R. E. Brownlee, S. Pulver, and H. C. Pillsbury. 1993. Use of poly-L-aspartic acid to inhibit aminoglycoside cochlear ototoxicity. Am. J. Otol. 14:352-359.
51. Humes, H. D., M. Sastrasinh, and J. M. Weinberg. 1984. Calcium is a competitive inhibitor of gentamicin-renal membrane binding interactions and dietary calcium supplementation protects against gentamicin nephrotoxicity. J. Clin. Invest. 73:134-147.
52. Hutchin, T., and G. Cortopassi. 1994. Proposed molecular and cellular mechanism for aminoglycoside ototoxicity. Antimicrob. Agents Chemother. 38:2517-2520.
53. Inouye, S., T. Niizato, T. Shomura, and I. Kitasato. 1989. Nephrotoxicity of dactimicin, a novel pseudodisaccharide aminoglycoside possessing the N-formimidoyl group, compared with that of astromicin, amikacin and other aminoglycoside antibiotics in animals. Drugs Exp. Clin. Res. 15:189-209.
54. Inouye, S., T. Niizato, U. Takeda, and T. Koeda. 1982. Protective effect of fosfomycin on the experimental nephrotoxicity induced by dibekacin. J. Pharmacobio-dyn. 5:659-669.
55. Kállay, Z., and P. M. Tulkens. 1989. Uptake and subcellular distribution of poly-L-aspartic acid, a protectant against aminoglycoside-induced nephrotoxicity, in rat kidney cortex, p. 189-192. In P. H. Bach and E. A. Lock (ed.), Nephrotoxicity: extrapolation from in vitro to in vivo, and animals to man. Plenum Press. London, United Kingdom.
56. Kaloyanides, G. J. 1984. Aminoglycoside-induced functional and biochemical defects in the renal cortex. Fundam. Appl. Toxicol. 4:930-943.
57. Kavutcu, M., O. Canbolat, S. Ozlurk, E. Olcay, S. Ulutepe, C. Ekinci, and I. Durak. 1996. Reduced enzymatic antioxidant defense mechanism in kidney tissues from gentamicin-treated guinea pigs: effects of vitamins E and C. Nephron 72:269-274.
58. Kays, S. E., W. A. Crowell, and M. A. Johnson. 1990. Influence of copper nutrition on gentamicin nephrotoxicity in rats. Magnesium Trace Elem. 9: 294-302.
59. Kikuchi, S., Y. Aramaki, H. Nonaka, and S. Tsuchiya. 1991. Effects of dextran sulphate on renal dysfunctions induced by gentamicin as determined by the kidney perfusion technique in rats. J. Pharm. Pharmacol. 43: 292-293.
60. Kishore, B. K., S. Ibrahim, and P. M. Tulkens. 1990. Increased levels of protein- and lipid-bound sialic acids in the renal cortex of rats injected with low doses of gentamicin. Toxicol. Lett. 51:59-65.
61. Kishore, B. K., S. Ibrahim, P. Lambricht, G. Laurent, P. Maldague, and P. M. Tulkens. 1992. Comparative assessment of poly-L-aspartic and poly-L-glutamic acids against gentamicin-induced renal lysosomal phospholipidosis, phospholipiduria and cell proliferation in rats. J. Pharmacol. Exp. Ther. 262:424-432.
62. Kishore, B. K., Z. Kállay, P. Lambricht, G. Laurent, and P. M. Tulkens. 1990. Mechanism of protection afforded by polyaspartic acid against gentamicin-induced phospholipidosis. I. Polyaspartic acid binds and displaces gentamicin from negatively-charged phospholipid layers. J. Pharmacol. Exp. Ther. 255:867-874.
63. Kishore, B. K., P. Lambricht, G. Laurent, P. Maldague, R. Wagner, and P. M. Tulkens. 1990. Mechanism of protection afforded by polyaspartic acid against gentamicin-induced phospholipidosis. II. Comparative in vitro and in vivo studies with poly-L-aspartic, poly-L-glutamic and poly-D-glutamic acids. J. Pharmacol. Exp. Ther. 255:875-885.
64. Klotman, P. E., and W. E. Varger. 1983. Reduction of renal blood flow and proximal bicarbonate reabsorption in rats by gentamicin. Kidney Int. 24: 638-643.
65. Kobayashi, Y., T. Tsuchiya, T. Ohgi, N. Taneichi, and Y. Koyama. 1992. Study on fluorination of 2,3-dideoxy-2,3-(N-tosylepimino)-alpha-D-allopy-ianosides, and synthesis of 3′-deoxy-3′-fluoro-kanamycin B and 3′,4′-dideoxy-3′-fluorokanamycin B. Carbohydr. Res. 230:89-105.
66. Kohlhepp, S. J., D. N. McGregor, S. J. Cohen, M. E. Kohlhepp, and D. N. Gilbert. 1992. Determinants of the in vitro interaction of polyaspartic acid and aminoglycoside antibiotics. J. Pharmacol. Exp. Ther. 263:1464-1470.
67. Kojima, R., and Y. Suzuki. 1990. Studies on the nephrotoxicity of aminoglycoside antibiotics and protection from these effects (9): protective effect of inositol hexasulfate against tobramycin-induced nephrotoxicity. Jpn. J. Pharmacol. 53:347-358.
68. Kojima, R., M. Ito, and Y. Suzuki. 1990. Studies on the nephrotoxicity of aminoglycoside antibiotics and protection from these effects (6): a mechanism for the suppressive action of latamoxef on intrarenal tobramycin level. Jpn. J. Pharmacol. 53:111-120.
69. Komatsuda, A., H. Wakui, H. Imai, A. B. Miura, H. Itoh, and Y. Tashima. 1996. Expression of 90-kDa heat shock protein within cellular crescents in human diseased kidneys. Nephrology 2:87-91.
70. Kondo, S. 1994. Development of arbekacin and synthesis of new derivatives stable to enzymatic modifications by methicillin-resistant Staphyloccus aureus. Jpn. J. Antibiot. 47:561-574.
71. Kosek, J. C., R. I. Mazze, and M. J. Cousins. 1974. Nephrotoxicity of gentamicin. Lab. Invest. 30:48-57.
72. Kotretsou, S., M.-P. Mingeot-Leclercq, V. Constantinou-Kokotou, R. Brasseur, M. P. Georgiadis, and P. M. Tulkens. 1995. Synthesis and antimicrobial and toxicological studies of amino acid and peptide derivatives of kanamycin A and netilmicin. J. Med. Chem. 38:4710-4719.
73. Lambricht, P. 1992. Evaluation systématique et prospective du potentiel toxique de nouveaux aminoglycosides, p. 168. Ph.D thesis. Université Catholique de Louvain, Louvain. Belgium.
74. Landau, D., and K. K. Kher. 1997. Gentamicin induced Bartter-like syndrome. Pediatr. Nephrol. 11:737-740.
75. Laurent, G., M. B. Carlier, B. Rollman, F. Van Hoof, and P. Tulkens. 1982. Mechanism of aminoglycoside-induced lysosomal phospholipidosis: in vitro and in vivo studies with gentamicin and amikacin. Biochem. Pharmacol. 31: 3861-3870.
76. Laurent, G., B. K. Kishore, and P. M. Tulkens. 1990. Aminoglycoside-induced phospholipidosis and nephrotoxicity. Biochem. Pharmacol. 40: 2383-2392.
77. Laurent, G., P. Maldague, M. B. Carlier, and P. Tulkens. 1983. Increased renal DNA synthesis in vivo after administration of low doses of gentamicin to rats. Antimicrob. Agents Chemother. 24:586-593.
78. Leonard, I., J. Zanen, D. Nonclercq, G. Toubeau, J. A. Heuson-Stiennon, J. F. Beckers, and G. Laurent. 1994. Modification of immunoreactive EGF and EGF receptor after acute tubular necrosis induced by tobramycin or cisplatin. Renal Fail. 16:583-608.
79. Levi, M., and R. E. Cronin. 1990. Early selective effects of gentamicin on renal brush-border membrane Na-Pi cotransport and Na-H exchange. Am. J. Physiol. 258:F1379-F1387.
80. Lortholary, O., F. Blanchet, D. Nochy, D. Heudes, N. Seta, P. Amirault, and C. Carbon. 1993. Effects of diltiazem on netilmicin-induced nephrotoxicity in rabbits. Antimicrob. Agents Chemother. 37:1790-1798.
81. Malis, C. D., L. C. Racusen, K. Solez, and A. Whelton. 1984. Nephrotoxicity of lysine and of a single dose of aminoglycoside in rats given lysine. J. Lab. Clin. Med. 103:660-676.
82. Miller, G. H., P. J. S. Chiu, and J. A. Waitz. 1978. Biological activity of Sch 21420, the 1-N-S-alphahydroxybeta aminopropionyl-derivative of gentamicin B. J. Antibiot. 31:688-696.
83. Mingeot-Leclercq, M. P., Y. Glupczynsky, and P. M. Tulkens. 1999. Aminoglycosides: activity and resistance. Antimicrob. Agents Chemother. 43: 727-737.
84. Mingeot-Leclercq, M. P., G. Laurent, and P. M. Tulkens. 1988. Biochemical mechanism of aminoglycoside-induced inhibition of phosphatidylcholine hydrolysis by lysosomal phospholipases. Biochem. Pharmacol. 37:591-599.
85. Mingeot-Leclercq, M. P., J. Piret, R. Brasseur, and P. M. Tulkens. 1990. Effect of acidic phospholipids on the activity of lysosomal phospholipases and on their inhibition by aminoglycoside antibiotics. I. Biochemical analysis. Biochem. Pharmacol. 40:489-497.
86. Mingeot-Leclercq, M. P., A. Schanck, M. F. Ronveaux-Dupal, M. Deleers, R. Brasseur, J. M. Ruysschaert, and P. M. Tulkens. 1989. Ultrastructural, physico-chemical and conformational study of the interactions of gentamicin and bis(beta-diethylaminoethylether)hexestrol with negatively charged phospholipid bilayers. Biochem. Pharmacol. 38:729-741.
87. Mingeot-Leclercq, M.-P., P. M. Tulkens, and R. Brasseur. 1992. Accessibility of aminoglycosides, isolated and in interaction with phosphatidylinositol, to water: a conformational analysis using the concept of molecular hydrophobicity potential. Biochem. Pharmacol. 44:1967-1975.
88. Mingeot-Leclercq, M. P., A. Van Schepdael, R. Brasseur, R. Busson, H. J. Vanderhaeghe, P. J. Claes, and P. M. Tulkens. 1991. New derivatives of kanamycin B obtained by modifications and substitutions in position 6″. II. In vitro and computer-aided toxicological evaluation, with respect to interactions with phosphatidylinositol. J. Med. Chem. 34:1476-1482.
89. Moestrup, S. K., S. Cui, H. Vorum, C. Bregengard, S. E. Bjorn, K. Norris, and E. I. Christensen. 1995. Evidence that epithelial glycoprotein 330/ megalin mediates uptake of polybasic drugs. J. Clin. Invest. 96:1404-1413.
90. Molitoris, B. A., and F. R. Simon. 1985. Renal cortical brush-border and basolateral membranes: cholesterol and phospholipid composition and relative turn-over. J. Membr. Biol. 83:207-215.
91. Moore, R. D., P. S. Lietman, and C. R. Smith. 1987. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J. Infect. Dis. 155:93-99.
92. Nakakuki, M., F. Yamasaki, T. Shinkawa, M. Kudo, M. Watanabe, and M. Mizota. 1996. Protective effect of human ulinastatin against gentamicin-induced acute renal failure in rats. Can. J. Physiol. Pharmacol. 74:104-111.
93. Nicolau, D. P., C. D. Freeman, P. P. Belliveau, C. H. Nightingale, J. W. Ross, and R. Quintilliani. 1995. Experience with once-daily aminoglycoside program administered to 2,184 adult patients. Antimicrob. Agents Chemother. 39:650-455.
94. Ohno, I., T. Shibasaki, H. Nakano, H. Matsuda, H. Matsumoto, T. Misawa, and O. Sakai. 1993. Effect of Sairei-to on gentamicin nephrotoxicity in rats. Arch. Toxicol. 67:145-147.
95. Parker, R. A., W. H. Bennett, and G. A. Porter. 1982. Animal models in the study of aminoglycoside nephrotoxicity, p. 235-267. In A. Whelton and H. C. Neu (ed.), The aminoglycosides: microbiology, clinical use and toxicology. Marcel Dekker, Inc., New York, N.Y.
96. Piret, J., B. K. Kishore, and P. M. Tulkens. 1992. Effect of substrate organization on the activity and on the mechanism of gentamicin-induced inhibition of rat liver lysosomal phospholipase A1. Biochem. Pharmacol. 43: 895-898.
97. Price, K. E. 1986. Aminoglycoside research 1975-1985: prospects for development of improved agents. Antimicrob. Agents Chemother. 29:543-548.
98. Prins, J. M., G. J. Weverling, K. de Blok, R. J. van Ketel, and P. Speelman. 1996. Validation and nephrotoxicity of a simplified once-daily aminoglycoside schedule and guidelines foi monitoring therapy. Antimicrob. Agents Chemother. 40:2494-2499.
99. Prins, J. M., G. J. Weverling, R. J. van Ketel, and P. Speelman. 1997. Circadian variations in serum levels and the renal toxicity of aminoglycosides in patients. Clin. Pharmacol. Ther. 62:106-111.
100. Priuska, E. M., and J. Schacht. 1997. Mechanism and prevention of aminoglycoside ototoxicity: outer hair cells as targets and tools. Ear Nose Throat J. 76:164-171.
101. Ramsammy, L. S., and G. J. Kaloyanides. 1988. The effect of gentamicin on the biophysical properties of phosphatidic acid liposomes is influenced by the OC=O group of the lipid. Biochemistry 27:8249-8254.
102. Ramsammy, L., C. Josepovitz, B. Lane, and G. J. Kaloyanides. 1990. Polyaspartic acid inhibits gentamicin-induced perturbation of phospholipid metabolism. Am. J. Physiol. 258:C1141-C1149.
103. Reiner, N. E., D. D. Bloxham, and W. L. Thompson. 1978. Nephrotoxicity of gentamicin and tobramycin given once daily or continuously in dogs. J. Antimicrob. Chemother. 4(Suppl. A):85-101.
104. Rodriguez-Barbero, A., J. M. Lopez-Novoa, and M. Arevalo. 1997. Involvement of platelet-activating factor in gentamicin nephrotoxicity in rats. Exp. Nephrol. 5:47-54.
105. Safirstein, R., P. Miller, and T. Kahn. 1983. Cortical and papillary absorptive defects in gentamicin nephrotoxicity. Kidney Int. 24:526-533.
106. Sakai, M., M. Z. Zhang, T. Homma, B. Garrick, J. A. Abraham, J. A. McKanna, and R. C. Harris. 1997. Production of heparin binding epidermal growth factor-like growth factor in the early phase of regeneration after acute renal injury. J. Clin. Invest. 99:2128-2138.
107. Sandhya, P., S. Mohandass, and P. Varalakshmi. 1995. Role of DL alpha-lipoic acid in gentamicin induced nephrotoxicity. Mol. Cell. Biochem. 145: 11-17.
108. Sandoval, R., J. Leiser, and B. A. Molitoris. 1998. Aminoglycoside antibi-otics traffic to the Golgi complex in LLC-PK1 cells. J. Am. Soc. Nephrol. 9: 167-174.
109. Schacht, J. 1997. Aminoglycoside ototoxicity: prevention in sight? Otolaryngol. Head Neck Surg. 117:1-4.
110. Schanck, A., R. Brasseur, M. P. Mingeot-Leclercq, and P. M. Tulkens. 1992. Interactions of aminoglycosides with phosphatidylinositol: a 15N nuclear magnetic resonance study. Magn. Reson. Chem. 30:11-15.
111. Shitara, T., Y. Kobayashi, T. Tsuchiya, and S. Umezawa. 1992. Synthesis of 5-deoxy-5-fluoro and 5-deoxy-5,5-difluoro derivatives of kanamycin B and its analogs. Study on structure-toxicity relationships. Carbohydr. Res. 232:273-290.
112. Silverblatt, F. J., and C. Kuehn. 1979. Autoradiography of gentamicin uptake by the rat proximal tubule cell. Kidney Int. 15:335-345.
113. Skopicki, H. A., D. Zikos, E. J. Sukowski, K. A. Fisher, and D. R. Peterson. 1996. Gentamicin inhibits carrier-mediated dipeptide transport in kidney. Am. J. Physiol. 270:F531-F538.
114. Smetana, S., S. Khalef, G. Kopolovic, Y. Bar-Khayim, Y. Birk, and S. Kacew. 1992. Effect of interaction between gentamicin and pyridoxal-5-phosphate on functional and metabolic parameters in kidneys of female Sprague-Dawley rats. Renal Fail. 14:147-153.
115. Smith, C. R., J. J. Lipsky, O. L. Laskin, D. B. Hellmann, E. D. Mellits, J. Longstreth, and P. S. Lietman. 1980. Double-blind comparison of the nephrotoxicity and auditory toxicity of gentamicin and tobramycin. N. Engl. J. Med. 302:1106-1109.
116. 2+ transport in rat renal brush-border membranes and its modulation by phosphatidic acid. Biochem. J. 214:37-46.
117. Song, B. B., D. J. Anderson, and J. Schacht. 1997. Protection from gentamicin ototoxicity by iron chelators in guinea pig in vivo. J. Pharmacol. Exp. Ther. 282:1-9.
118. Sturm, A. W. 1989. Netilmicin in the treatment of gram-negative bacteremia: simple daily versus multiple daily dosage. J. Infect. Dis. 159:931-937.
119. Sundin, D. P., C. Meyer, R. Dahl, A. Geerdes, R. Sandoval, and B. A. Molitoris. 1997. Cellular mechanism of aminoglycoside tolerance in long-term gentamicin treatment. Am. J. Physiol. 41:C1309-C1318.
120. Swan, S. K., D. N. Gilbert, S. J. Kohlhepp, P. W. Kohnen, and W. M. Bennett. 1993. Pharmacologic limits of the protective effect of polyaspartic acid on experimental gentamicin nephrotoxicity. Antimicrob. Agents Chemother. 37:347-348.
121. Tabatabay, C. A., L. H. Young, D. J. D'Amico, and K. R. Kenyon. 1990. Immunocytochemical localization of gentamicin in the rabbit retina following intravitreal injection. Arch. Ophthalmol. 108:723-726.
122. Takahashi, Y., C. Ueda, T. Tsuchiya, and Y. Kobayashi. 1993. Study on flurination-toxicity relationships. Syntheses of I-N-[(2R,3R)- and (2R,3S)-4-amino-3-fluoro-2-hydroxybutanoyl] derivatives of kanamycins. Carbohydr. Res. 249:57-76.
123. ter Braak, E. W., P. J. de Vries, K. P. Bouter, S. G. van der Vegt, G. C. Dorrestein, J. W. Nortier, and H. A. Verbrugh. 1990. Once-daily dosing regimen for aminoglycoside plus beta-lactam combination therapy of serious bacterial infections: comparative trial with netilmicin plus ceftriaxone. Am. J. Med. 89:58-65.
124. Thibault, N., L. Grenier, M. Simard, M. G. Bergeron, and D. Beauchamp. 1994. Attenuation by daptomycin of gentamicin-induced experimental nephrotoxicity. Antimicrob. Agents Chemother. 38:1027-1035.
125. Todd, J. H., and G. H. Hottendorf. 1997. Poly-L-aspartic acid protects cultured human proximal tubule cells against aminoglycoside-induced electrophysiological alterations. Toxicol. Lett. 90:217-221.
126. Todd, J. H., D. A. Sens, D. J. Hazen-Martin, J. E. Bylander, B. J. Smyth, and M. A. Sens. 1992. Aminoglycoside antibiotics alter the electrogenic transport properties of cultured human proximal tubule cells. Toxicol. Pathol. 20:608-616.
127. Toubeau, G., G. Laurent, M. B. Carlier, S. Abid, P. Maldague, J. A. Heuson-Stiennon, and P. M. Tulkens. 1986. Tissue repair in rat kidney cortex after short treatment with aminoglycosides at low doses: a comparative biochemical and morphometric study. Lab. Invest. 54:385-393.
128. Tsuchiya, T., T. Shitara, S. Umezawa, T. Takeuchi, M. Hamada, N. Tomono, and E. Umemura. 1993. Synthesis of low-toxicity, 5-deoxy-5-fluoro and 5-deoxy-5,5-difluoro derivatives of arbekacin and its analogs, and study of structure-toxicity relationships. Carbohydr. Res. 240:307-312.
129. Tsuchiya, T., Y. Takahashi, Y. Kobayashi, S. Umezawa, and H. Umezawa. 1985. Synthesis of 3′-deoxy-3′-fluorokanamycins A and B active against resistant bacteria. J. Antibiot. (Tokyo) 38:1287-1290.
130. Tulkens, P. M. 1986. Experimental studies on nephrotoxicity of aminoglycosides at low doses: mechanisms and perspectives. Am. J. Med. 80(Suppl. 6B):105-114.
131. Tulkens, P. M. 1989. Nephrotoxicity of aminoglycosides. Toxicol. Lett. 46: 107-123.
132. Tulkens, P. M., F. Clerckx-Braun, J. Donnez, S. Ibrahim, Z. Kallay, P. Jacqmin, and M. Gersdorff. 1988. Safety and efficacy of aminoglycosides once-a-day: experimental data and randomized, controlled evaluation in patients suffering from pelvic inflammatory disease. J. Drug Dev. 1(Suppl. 3):71-82.
133. Tulkens, P. M., M. P. Mingeot-Leclercq, G. Laurent, and R. Brasseur. 1990. Conformational and biochemical analysis of the interactions phospholipids-aminoglycoside antibiotics in relation with their toxicity, p. 63-93. In R. Brasseur (ed.), Molecular description of biological membrane components by computer-aided conformational analysis. CRC Press, Inc., Boca Raton, Fla.
134. Van Bambeke, F., P. M. Tulkens, R. Brasseur, and M.-P. Mingeot-Leclercq. 1995. Aminoglycoside antibiotics induce aggregation but not fusion of negatively-charged liposomes. Eur. J. Pharmacol. 289:321-333.
135. Vandewalle, A., N. Farman, J. P. Morin, J. P. Fillastre, P. Y. Hatt, and J. P. Bonvalet. 1981. Gentamicin incorporation along the nephron: autoradiographic study on isolated tubules. Kidney Int. 19:529-539.
136. Walker, P. D., and S. V. Shah. 1987. Gentamicin enhanced production of hydrogen peroxide by renal cortical mitochondria. Am. J. Physiol. 253: C495-C499.
137. Walker, R. J., and G. G. Duggin. 1988. Drug nephrotoxicity. Annu. Rev. Pharmacol. Toxicol. 28:331-345.
138. Watanabe, M. 1978. Drug-induced lysosomal changes and nephrotoxicity in rats. Acta Pathol. Jpn. 28:867-889.
139. Wedeen, R. P., V. Batuman, C. Cheeks, E. Marquet, and H. Sobel. 1983. Transport of gentamicin in rat proximal tubule. Lab. Invest. 48:212-223.
140. Weinberg, J. M. 1986. The role of cell calcium overload in nephrotoxic renal tubular cell injury. Am. J. Kidney Dis. 8:284-291.
141. Whittem, T., K. Parton, and K. Turner. 1996. Effect of polyaspartic acid on pharmacokinetics of gentamicin after single intravenous dose in the dog. Antimicrob. Agents. Chemother. 40:1237-1241.
142. Williams, P. D., and G. H. Hottendorf. 1985. Inhibition of renal membrane binding and nephrotoxicity of gentamicin by polyasparagine and polyaspartic acid in the rat. Res. Commun. Chem. Pathol. Pharmacol. 47:317-320.
143. Zheng, G., D. R. Bachinsky, I. Stamenkovic, D. K. Strickland, D. Brown, G. Andres, and R. T. McCluskey. 1994. Organ distribution in rats of two members of the low-density lipoprotein receptor gene family, gp330 and LRP/alpha 2MR, and the receptor-associated protein (RAP). J. Histochem. Cytochem. 42:531-542.